TGF-β-mediated suppression of NK cell function and targeting strategies in tumor immunotherapy
Authors:
- 22 January 2026
- journal article
- review article
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 219, 105141
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (8257210)
- National Key Research and Development Program of China Stem Cell and Translational Research
This publication has 171 references indexed in Scilit:
- Interleukin-21 engineering enhances NK cell activity against glioblastoma via CEBPDCancer Cell, 2024
- Disrupting Smad3 potentiates immunostimulatory function of NK cells against lung carcinoma by promoting GM-CSF productionCellular and Molecular Life Sciences, 2024
- Simultaneous targeting of TGF-β/PD-L1 synergizes with radiotherapy by reprogramming the tumor microenvironment to overcome immune evasionCancer Cell, 2021
- Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Patients with Esophageal Adenocarcinoma: Results from a Phase 1 CohortTargeted Oncology, 2021
- Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant gliomaInvestigational New Drugs, 2020
- NK Cells Stimulate Recruitment of cDC1 into the Tumor Microenvironment Promoting Cancer Immune ControlCell, 2018
- Augmented anti-tumor activity of NK-92 cells expressing chimeric receptors of TGF-βR II and NKG2DCancer Immunology, Immunotherapy, 2017
- CX3CR1‐dependent recruitment of mature NK cells into the central nervous system contributes to control autoimmune neuroinflammationEuropean Journal of Immunology, 2016
- A role of the latent TGF‐beta 1‐binding protein in the assembly and secretion of TGF‐beta 1.The EMBO Journal, 1991
- Characterization of the latent transforming growth factor ß complex in BoneJournal of Bone and Mineral Research, 1990